#The neutralization titer (Nt) was assayed with EV71/E59 (B4 subgenotype) and the GMT ± SE was shown. $Three groups were immunized three times with 10 µg (high dose; n = 4) or 5 µg (low dose; n = 4) o
Succumbed to BEBOV challenge. a rVSV blend; rVSV-SEBOV-GP plus rVSV-ZEBOV-GP, rVSV Prime-boost; rVSV-SEBOV-GP first then rVSV-ZEBOV-GP 14 days after. −22; day of boost.b Days after BEBOV challenge, D
Ab Antibody titer. *Nicotine replacement therapy users and subjects with missing titers at months 4 to 6 were excluded; the participants on active treatment were separated into three responder subgrou
